Against the demonstrated high efficacy of this approach are several drawbacks. First, studies that have compared the outcome of combined therapy versus brachytherapy monotherapy in early to intermediate prognosis patients have failed to demonstrate superiority in the combined therapy arm (23).

Combined therapy regimens may also be more toxic than monotherapy approaches (24). Finally, combined therapy is expensive.